Overview

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide, Formoterol Fumarate Drug Combination